StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) company profile

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.00−0.02 (-0.66%)

Close on Nov 17, 2026Market cap $519.43MP/E –Yield –

About Entera Bio

Biological Products, (No Diagnostic Substances), SIC 2836

Entera Bio Ltd. is a clinical-stage biopharmaceutical company that develops oral tablet formulations of peptides and protein replacement therapies. The company utilizes its proprietary delivery platform to stabilize large peptides in the gastrointestinal tract and support absorption into the bloodstream. Its drug pipeline includes EB613, an oral bone-building tablet candidate for postmenopausal osteoporosis, as well as EB612 for hypoparathyroidism. The company also advances early-stage oral programs for obesity, metabolic disorders, and rare gastrointestinal diseases. Its target consumers are patients living with chronic conditions that typically require frequent injections.

Entera Bio is headquartered in Jerusalem, Israel, where it maintains office, research, and laboratory spaces. As a development-stage enterprise, the company conducts preclinical research and clinical trials across multiple programs, with its lead candidate tested in hundreds of clinical trial participants. The company operates through its Israeli organization alongside a consolidated subsidiary and manages operations across domestic and foreign jurisdictions.

Summary of the business section of Entera Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Entera Bio Ltd.
Headquarters
Jerusalem, Israel
Address
Kiryat Hadassah, Minrav Building, Fifth Floor 9112002
Phone
972-2-532-7151
Employees
20, Dec 31, 2024
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman, Tel-Aviv, Israel

Stock & identifiers

Ticker
ENTX
Exchange
Nasdaq
IPO date
Jun 29, 2018
Shares outstanding
173M, Aug 3, 2026
Public float
$84.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1638097
CUSIP
M40527109
FIGI
BBG000R1K184
Share class FIGI
BBG001T8ZSW3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Miranda Jayne ToledanoChief Executive Officer, Director847,135
Riccardo Paolo CamisascaChief Medical Officer–
Hillel GalitzerChief Operating Officer163,566
Gregory BurshteinChief of R&D189,033
Dana Yaacov-GarbeliChief Financial Officer258,172
Leslie Velka GautamChief Business Officer–
Yonatan MalcaDirector100,231
Haya TaitelDirector119,269
Steven D. RubinDirector34,117
Sean EllisDirector208,132
Geno J. GermanoDirector65,014
Gerald M. OstrovDirector75,657
Gerald M. LiebermanDirector344,654

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Non Principal Executive Officer And Non Executive Officer
$518.00K$437.00K$518.00K$223–
FY2025
Principal Executive Officer
$1.48M$1.35M$518.00K$223–
FY2024
Non Principal Executive Officer And Non Executive Officer
$485.00K$849.00K$485.00K$212–
FY2024
Principal Executive Officer
$1.15M$2.19M$485.00K$212–
FY2023
Non Principal Executive Officer And Non Executive Officer
$385.00K$314.00K$385.00K$21000–
FY2023
Principal Executive Officer
$950.00K$483.00K$385.00K$21000–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsOtherTotalvs. prior year
Miranda Toledano
Chief Executive Officer and director
$490$330$590$72$1.48K+29%
Hillel Galitzer
Chief Operating Officer
$282$48$176$25$5310%
Gregory Burshtein
Chief of Research and Development
$217$48$202$37$504+50%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 29, 2018
Offer price
$8.00
Exchange
Nasdaq
First trading day
Jun 28, 2018
First-day close
$6.28-21.5%
Lock-up ends (est.)
Dec 25, 2018

“The initial public offering price is $8.00 per unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2024, we had a total of 20 employees, of whom 18 are full-time employees all based in Israel.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?